Ashwini Arvind (she/her) @dr_ash_arvind X Profile

Ashwini Arvind (she/her)

@dr_ash_arvind

Followers

152

Following

193

Media

2

Statuses

37

GI fellow @UTSWInternalMed | AASLD Emerging Liver Scholar 2021 | Former Research Fellow @MGH_GI | @UniofOxford and @ImperialCollege alumnus 🇬🇧

Dallas, TX

Joined August 2021

Don't wanna be here? Send us removal request.

Jeremy Louissaint

@jlouissaint89

10 months

🏅 The taste of victory!! @AASLDtweets #TLM2024 #DebateWinners @AminFa91 @dr_ash_arvind

1

3

40

Thomas G. Cotter, MD MS

@TCotterMD

10 months

The sweet taste of success! Well done @dr_ash_arvind @AminFa91 @docamitgs @UTSWGI Doing @UTSWMedCenter proud on winning @AASLDtweets Liver Academic Debates. Valiant effort from @RushMedical 👏

1

5

44

Ariel Aday

@ArielAday

10 months

It is no surprise to me that UTSW won the academic debate at #TLM2024 🥇 Lots of practice and late nights for these two really paid off! Winners of the Liver Cup 🏆 Congratulations! @AminFa91 @dr_ash_arvind @docamitgs

2

7

65

Nicole Rich

@nicole_rich8

2 years

Great work by 🌟fellow @dr_ash_arvind on this ☺️

Evidence-Based GI: An ACG Publication (EBGI)

@ACG_EBGI

2 years

1/ It's #EBGITweetorial🧵w/ @DrKashyapC ! ‘’HCC incidence rates are 2%-3% in US patients with cirrhosis regardless of etiology’’ 📜Summary: https://t.co/Wkle45jXRz 🎧 : https://t.co/bAJWt56cbw 📰 in @AGA_Gastrojournal. Current🔗: https://t.co/936S8vdWJ4

0

2

12

Jackie Henson

@jackie_henson

3 years

Thanks to @LiverInt for publishing our work evaluating performance of the ASCVD risk score in individuals with NAFLD in the MESA cohort. Risk was underestimated in some groups, particularly in women. More work is needed in this area. @Duke_GI_ https://t.co/EhS7oDVG6P

onlinelibrary.wiley.com

Background and Aims Non-alcoholic fatty liver disease (NAFLD) is associated with a high risk of cardiovascular disease. Whether risk scores developed in the general population accurately assess...

1

2

19

Ashwini Arvind (she/her)

@dr_ash_arvind

3 years

🥰🥰

James D. Haddad, MD, FACP

@JamesHaddadMD

3 years

I'm so excited to work with our incoming class of fellows - we had some *very* strong candidates this year! Congratulations! #GITwitter #GIFellow #MedTwitter #MatchDay @dr_ash_arvind

0

3

Healio Gastroenterology

@HealioGastro

3 years

#ICYMI from #TLM2022: @dr_ash_arvind reported ‘significant’ #racial, #ethnic #disparities exist in curative treatment for early-stage #HCC #LiverMtg22 #LiverTwitter

healio.com

WASHINGTON — Fewer Black and Hispanic patients received curative treatment for early-stage hepatocellular carcinoma compared with white patients, according to research presented at The Liver Meeting....

0

1

2

Ashwini Arvind (she/her)

@dr_ash_arvind

3 years

Grateful for the opportunity to present our findings on racial disparities in curative treatment for early stage HCC in this morning's parallel session @AASLDtweets. Thanks to @nicole_rich8 for her inspiring mentorship, and to @docamitgs and @UTSWInternalMed for their support

3

4

39

Ashwini Arvind (she/her)

@dr_ash_arvind

3 years

The best time presenting our work at #DDW2022! Thanks to my wonderful mentors @nicole_rich8 and @docamitgs and to @UTSWInternalMed and @DinoKazi for their constant support

Nicole Rich

@nicole_rich8

3 years

Proud of 🌟 mentee Dr Ash Arvind @UTSWInternalMed presenting our work at #DDW2022 on racial disparities in receipt of curative HCC treatment @UTSWGI @docamitgs

1

4

23

Ashwini Arvind (she/her)

@dr_ash_arvind

4 years

Congrats to a wonderful mentor!🍾 @KathleenCoreyMD @MGH_GI @MghNafld

0

1

9

Ashwini Arvind (she/her)

@dr_ash_arvind

4 years

Interesting talk by Shuyun Rao. TGF-beta proteins may serve as accurate biomarkers in early detection of #HCC #LiverCancerSIG #LiverMTG2021 @docamitgs @nicole_rich8 @AndrewMMoon

0

2

9

Vinay Sundaram, MD, MSc

@VinaySundaramMD

4 years

Thank you to our amazing ELS scholars who presented their research this morning @dr_ash_arvind @PhoebeLinMD @lamatthews22 #EmilyTruong And special thank you to our coaches and mentors @NancyReau @BrettEFortuneMD @DawnPiercy2 @NoureddinMD @docamitgs @john_ricemd @YucaSpice

0

7

37

Ashwini Arvind (she/her)

@dr_ash_arvind

4 years

Enjoyed presenting our research on risk of HCC in pts with LR-3 observations. Inspiring to hear from other #emergingliverscholars. Excited to see what you get up to next! @docamitgs @VinaySundaramMD @NancyReau @BrettEFortuneMD @DawnPiercy2 @PhoebeLinMD @lamatthews22 #LiverMtg21

2

35

United Network for Organ Sharing (UNOS)

@UNOSNews

4 years

The US organ donation and transplant system requires thousands of people working together every day. Our new video shows this lifesaving journey, starting with the generous donor and their family. Watch below. #DonateLife #TransplantTwitter

6

92

207

Elliot Tapper

@ebtapper

4 years

So your patient’s liver surface is nodular. Do they have #cirrhosis? they often don’t! 1️⃣many people with nodularity do NOT have F3/F4 2️⃣true even for people with lots of nodularity This study used MRI and software to 📏nodularity https://t.co/o0rS5BAa3h #LiverTwitter

9

37

154

George Ioannou

@gnioannou

4 years

Thank you to @JHepatology for letting me summarize my thoughts on Epidemiology and Risk-stratification of NAFLD-associated Hepatocellular Carcinoma. https://t.co/P1w4REqsk7 Key concepts summarized by each Figure

journal-of-hepatology.eu

Non-alcoholic fatty liver disease (NAFLD) is projected to become the leading cause of hepatocellular carcinoma (HCC) in many countries. Many risk factors for NAFLD are also independently associated...

1

20

44

Ashwini Arvind (she/her)

@dr_ash_arvind

4 years

Fascinating review on the interplay between NAFLD and type 2 diabetes! @KathleenCoreyMD @MghNafld @MGH_GI

0

1

6